ArticleBMC endocrine disorders2026
Serum long noncoding RNA human plasmacytoma variant translocation 1 (PVT1) expression levels in Egyptians type 2 diabetic patients and its correlation with severity of diabetic nephropathy.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContinuous rise in the global incidence of type 2 diabetes mellitus (T2DM) has been associated with a marked increase in diabetic kidney disease (DKD). Despite that, the clinical markers that are currently used for diagnosing diabetic nephropathy (DN) still not reliable. In recent years, long non-coding RNAs (lncRNAs) have drawn growing attention, with accumulating evidence linking their dysregulated expression to the onset and progression of DKD. AIM OF THE STUDY: This study aimed to assess serum lncRNA PVT1 expression in Egyptian patients with type 2 diabetes mellitus and evaluate its association with the progression and severity of diabetic kidney disease. PATIENTS AND
methodsA total of 80 adults were enrolled and divided into four groups (20 each): three type 2 diabetes mellitus groups stratified by urinary albumin-to-creatinine ratio (UACR; normal, moderately increased, and severely increased) and one healthy control group. Diabetic patients were further classified by fundus examination into those with and without retinopathy. All participants underwent clinical and laboratory evaluation, and serum lncRNA PVT1 expression was quantified using real-time PCR.
resultsSerum lncRNA PVT1 expression was markedly elevated in patients with type 2 diabetes compared to healthy controls, with significantly higher levels observed in G3 relative to G1. A significant positive correlation was found between PVT1 expression and UACR, serum creatinine, age, BMI, fasting blood glucose, 2-hour postprandial glucose, and HbA1c. Conversely, PVT1 demonstrated a significant negative correlation with eGFR, ALT, and platelet count. Notably, PVT1 emerged as the sole independent predictor of proteinuria among diabetic patients.
conclusionlncRNA PVT1 is significantly overexpressed in T2DM patients and correlates with glycemic status and renal dysfunction. It serves as a potential reliable biomarker for DKD severity and progression and represents a potential therapeutic target. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.